SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Easton DF, Ford D, Bishop DT. Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 1995; 56: 26571.
  • 2
    Ford D, Easton DF, Stratton MR, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Gharg-Claude J, Sobol H, Teare MD, et al. Genetic heterogeneity and penetrance analysis of BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62: 67689.
  • 3
    Struewing JP, Hartge P, Wacholdes S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 14018.
  • 4
    Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, Wacholder S, Tulinius H, Eyfjord JE. Population-based study of risk of breast cancer in carriers of BRCA2 mutations. Lancet 1998; 352: 13379.
  • 5
    Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan X, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS. AIB1, a steroid coactivator amplified in breast and ovarian cancer. Science 1997; 277: 9658.
  • 6
    Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000; 20: 50417.
  • 7
    Bautista S, Valles H, Walker RL, Anzick S, Zeillinger R, Melzer P, Theiller C. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res 1998; 4: 29259.
  • 8
    Bouras T, Southey MC, Venter DJ. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/new. Cancer Res 2001; 61: 9037.
  • 9
    Ghadimi, Schrock E, Walker RL, Wangsa D, Jauho A, Meltzer PS, Ried T. Specific aberration and amplification of AIB1 in pancreatic cancer. Am J Pathol 1999; 154: 5306.
  • 10
    Sakakura C, Hagiwara A, Yasuka R, Fujita Y, Nakanishi M, Masuda K, Kimura A, Nakamura Y, Inazawa J, Abe T, Yamagishi H. Amplification and over-statement of the AIB1 nuclear receptor co-activator gene in primary gastric cancer. Int J Cancer 2000; 89: 21723.
  • 11
    Wang Z, Rose DW, Hermanson O, Liu F, Herman T, Wu W, Szeto D, Gleibeman A, Krones A, Pratt K, Rosenfeld R, Glass CK, Rosenfeld MG. Regulation of somatic growth by the p160 coactivator p/CIP. Proc Natl Acad Sci USA 2000; 97: 1354954.
  • 12
    Shirazi SK, Bober MA, Coetzee GA. Polymorphic exonic CAG microsatellites in the gene amplified in breast cancer (AIB1 gene). Clin Genet 1998; 54: 1023.
  • 13
    Hayashi Y, Yamamoto M, Ohmori S, Kikumori T, Imai T, Funahashi H, Seo H. Polymorphism of homopolymorphic glutamine in coactivators for nuclear hormone receptors. Endocrine J 1999; 46: 27984.
  • 14
    Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, Daly MB, Narod SA, Brunet JS, Vesprini D, Garber JE, Lynch HT, et al. Modification of BRCA1 and BRCA2 associated breast cancer risk by the AIB1 genotype and reproductive history. Cancer Res 2001; 61: 54204.
  • 15
    Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willet WC, Speizer FE, Brown M, Hunter DJ. Polymorphic repeat in AIB1 does not alter breast cancer risk. Breast Cancer Res 2000; 2: 37885.
  • 16
    Antoniou AC, Phrouah PD, McMullan G, Day NE, Stratton MR Peto J, Ponder BJ, Easton DF. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002; 86: 7683.
  • 17
    Lange K, Weeks D, Boehnke M. Programs for pedigree analysis: MENDEL, FISHER and dGENE. Genet Epidemiol 1988; 5: 4712.
  • 18
    Kadouri L, Easton DF, Edwards S, Hubert A, Kote-Jarai Z, Glaser B, Durocher F, Abeliovich D, Peretz T, Eeles RA. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer 2001; 85: 3640.
  • 19
    Easton DF, Peto J, Babiker A. Floating absolute risks—an alternative to choosing an arbitrary group in survival analysis and case-control studies. Stat Med 1991; 10: 102535.
  • 20
    Phelan CM, Rebbeck TR, Weber BL, Devilee P, Ruttledge MH, Lynch HT, Lenoir GM, Stratton MR, Easton DF, Ponder BA, Cannon-Albright L, Larsson C, et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 1996; 12: 30911.
  • 21
    Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT Weber BL, Brown M. Modification of BRCA1-associated breast cancer risk by polymorphic androgen-receptor CAG repeat. Am J Hum Genet 1999; 64: 13717.
  • 22
    Wang W, Spurdle AB, Kolachan AB, Bove B, Modan B, Ebbers SM, Suthers G, Tucker MA, Kaufman DJ, Boody MM, Tarone RE, Daly M, et al. A single nucleotide polymorphism in the 5′ untranslated region of RAD51 risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2001; 10: 95560.
  • 23
    Levy-Lahad E, Lahad A, Eisenberg S, Dagan E, Paperana T, Kasinetz L, Catane R, Kaufman B, Beller U, Renbaum P, Gershoni-Baruch R. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA 2001; 98: 32326.
  • 24
    Zhuchenko O, Baily J, Bonnen P, Ashizawa T, Stockton DW, Amos C, Cobyns WB, Subramony SH, Zoghbi HY, Lee CC. Autosomal dominant cerebellar ataxia (SCA6) associated with polyglutamine expansions in the a1A-voltage-dependent calcium channel. Nat Genet 1997; 15: 629.
  • 25
    David G, Abbas N, Stevanin G, Durr A, Yvert G, Cancel G, Weber C, Imbert G, Saudou F, Antoniou E, Drabkin H, Gemmill R, et al. Cloning of the SCA7 gene reveals a highly unstable CAG expansion. Nat Genet 1997; 17: 6570.
  • 26
    La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352: 779.
  • 27
    Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997; 89: 16670.
  • 28
    Young IE, Kurian KM, Mackenzie MA, Kunkler IH, Cohen BB, Hooper ML, Wyllie AH. The CAG repeat within the androgen receptor gene in male breast cancer patients. J Med Genet 2000; 37: 13940.
  • 29
    Chamberline N, Driver E, Miesfeld R. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acid Res 1994; 22: 31816.
  • 30
    Gerber HP, Seipel K, Georgiev O, Hofferer M, Hug M, Rusconi S, Shaffner W. Transcriptional activation modulated by homopolymorphic glutamine and proline stretches. Science 1994; 263: 80811.
  • 31
    Patel MS, Cole DE, Smith JD, Hawker GA, Wong B, Trang H, Veith R, Melzer P, Rubin LA. Alleles of the estrogen receptor alpha-gene and an estrogen receptor cotranscriptional activator gene, amplified in breast cancer (AIB1) are associated with quantitative calcaneal ultrasound. J Bone Miner Res 2000; 15: 22319.
  • 32
    Jernstrom H, Chu W, Vesprini D, Tao Y, Majeed N, Deal C, Pollak M, Narod SA. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab 2001; 72: 14454.
  • 33
    Armes JE, Venter DJ. The pathology of inherited breast cancer. Pathology 2002; 34: 30914.
  • 34
    Gudas JM, Nguyen H, Li T, Cowan KH. Hormone dependent regulation of BRCA1 in human breast cancer cells. Cancer Res 1995; 55: 45615.
  • 35
    Fan S, Wang JA, Yuan R, Ma Y, Mey Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID, Rosen EM. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999; 284: 13546.
  • 36
    Spillman MA, Bowcock AM. BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen. Oncogen 1996; 13: 163945.
  • 37
    Rajan JV, Wang M, Marquis ST, Chodosh LA. BRCA2 is coordinately regulated with BRCA1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci USA 1996; 93: 1307883.
  • 38
    Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Offit K. Risk-reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 160915.
  • 39
    Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, vant'Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 161622.
  • 40
    Zheng L, Annab LA, Afshari CA, Lee WH, Boyer TG. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci USA 2001; 98: 957892.